WO2015138186A3 - Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists - Google Patents

Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists Download PDF

Info

Publication number
WO2015138186A3
WO2015138186A3 PCT/US2015/018401 US2015018401W WO2015138186A3 WO 2015138186 A3 WO2015138186 A3 WO 2015138186A3 US 2015018401 W US2015018401 W US 2015018401W WO 2015138186 A3 WO2015138186 A3 WO 2015138186A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurokinin
compositions
receptor antagonists
methods
induced cardiomyopathy
Prior art date
Application number
PCT/US2015/018401
Other languages
French (fr)
Other versions
WO2015138186A2 (en
Inventor
Giselle C. MELENDEZ
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of WO2015138186A2 publication Critical patent/WO2015138186A2/en
Publication of WO2015138186A3 publication Critical patent/WO2015138186A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Abstract

The presently disclosed subject matter provides methods and compositions for the treatment of anthracycline-induced cardiomyopathy, particularly doxorubicin- induced cardiomyopathy, using neurokinin-1 (NK-1) receptor antagonists.
PCT/US2015/018401 2014-03-12 2015-03-03 Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists WO2015138186A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461951605P 2014-03-12 2014-03-12
US61/951,605 2014-03-12

Publications (2)

Publication Number Publication Date
WO2015138186A2 WO2015138186A2 (en) 2015-09-17
WO2015138186A3 true WO2015138186A3 (en) 2015-12-10

Family

ID=54072567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/018401 WO2015138186A2 (en) 2014-03-12 2015-03-03 Methods and compositions for treating anthracycline-induced cardiomyopathy using neurokinin-1 receptor antagonists

Country Status (1)

Country Link
WO (1) WO2015138186A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108697646A (en) 2016-02-04 2018-10-23 干细胞诊疗公司 The pharmaceutical composition and method of cardiac toxic for resisting chemotherapy-induced

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252714A1 (en) * 2003-01-17 2006-11-09 Berger Stuart A Pharmaceutical compositions and methods for treating multidrug resistant cancer
US20140057861A1 (en) * 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252714A1 (en) * 2003-01-17 2006-11-09 Berger Stuart A Pharmaceutical compositions and methods for treating multidrug resistant cancer
US20140057861A1 (en) * 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MELENDEZ ET AL.: "Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.", CARDIOVASC RES., vol. 92, no. 3., 1 December 2011 (2011-12-01), pages 420 - 429, XP055103403, ISSN: 0008-6363 *
VO ET AL.: "Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: Results from a population-based study.", J CANCER EPIDEMIOL., vol. 21, no. 8, 2012, pages 946 - 12, XP055238887, ISSN: 1687-8558 *

Also Published As

Publication number Publication date
WO2015138186A2 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12018500457A1 (en) New phenoxymethyl derivatives
EP3481402A4 (en) Compounds, compositions, and methods for the treatment of disease
MY191581A (en) Anti-pd-1 antibodies
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
EP3484504A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
IL273300A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
MY192927A (en) Fused bicyclic compounds for the treatment of disease
WO2015168643A3 (en) Compositions and methods related to engineered fc constructs
MX369623B (en) Fused bicyclic compounds for the treatment of disease.
IL280809B (en) Novel compositions, their use, and methods for their formation
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
EP3538189A4 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
PH12018500829A1 (en) Novel heterocyclic antiestrogens
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
EP3186269A4 (en) Compositions, methods and kits for treating complement related disorders
GB2540427B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene (1234yf)
EP3377105A4 (en) Compositions for treating ectopic calcification disorders, and methods using same
EP3310358A4 (en) Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
WO2015200534A3 (en) Small molecule agonists of neurotensin receptor 1
PH12016501483A1 (en) P-substituted asymmetric ureas and medical uses thereof
EP3212640A4 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15761545

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15761545

Country of ref document: EP

Kind code of ref document: A2